JP7359909B2 - A method for producing an oral composition, a method for improving the adhesion of an oral composition to an oral application part, and a method for improving retention of an oral composition in an oral application part. - Google Patents

Description

The present invention relates to an oral composition and a method for enhancing the adhesion of the oral composition to the oral mucosa.

JP-A-60-226806 (Patent Document 1) discloses an oral cavity composition for gingival massage to prevent and treat gingivitis and the like. Specifically, it is disclosed that this oral composition has a predetermined composition, thereby achieving an excellent massage effect and high absorption of the active ingredient blended into the oral composition.

Japanese Unexamined Patent Publication No. 60-226806

In the technical field related to oral compositions, it has been pointed out that how well the oral composition adheres to and maintains the always wet oral mucosa is important in order to effectively express its medicinal efficacy. Oral compositions generally include water-soluble polymers for the purpose of imparting adhesion and affinity to the oral mucosa, so technological development is underway to enhance the functions of these water-soluble polymers. There is. However, an oral composition having the desired adhesion and affinity to the oral mucosa has not yet been obtained.

The present invention was made in view of the above circumstances, and aims to provide an oral composition with improved adhesion to the oral mucosa and a method for enhancing the adhesion of the oral composition to the oral mucosa.

Surprisingly, the present inventors have discovered that an oral composition containing a water-soluble polymer and a predetermined amount of one or more selected from the group consisting of carbazochrome, carbazochrome derivatives, and their salts, It has been found that when both components are contained, the adhesion to oral mucosa is significantly improved. The present invention was completed based on this knowledge and provides the following inventions.

The composition for oral cavity according to the present invention contains a first component that is one or more selected from the group consisting of carbazochrome, derivatives of carbazochrome, and salts thereof, and a second component that is a water-soluble polymer. A composition containing 0.04 w/w % or less of the first component.

The second component preferably contains one or more selected from the group consisting of hydroxypropyl methylcellulose, carboxyvinyl polymer, sodium alginate, and pullulan.

It is preferable that the second component contains two or more kinds of compounds.
It is preferable that the oral cavity composition contains the second component from 0.001 w/w% to 20 w/w%.

The oral cavity composition preferably contains a third component that is an oily base. Furthermore, it is preferable to contain a fourth component which is a non-steroidal anti-inflammatory agent. Preferably, the fourth component is allantoin.

The method for enhancing the adhesion of an oral composition to oral mucosa according to the present invention allows the oral composition to adhere to the oral cavity.

According to the present invention, it is possible to provide an oral composition with improved adhesion to the oral mucosa and a method for enhancing the adhesion of the oral composition to the oral mucosa.

EMBODIMENT OF THE INVENTION Hereinafter, the form for implementing this invention is demonstrated in detail. However, the present invention is not limited to the following embodiments.

Here, in this specification, the notation in the format "X to Y" means the upper and lower limits of the range (i.e., from X to Y), and when there is no unit described for X and only for Y. In this case, the units of X and Y are the same. Furthermore, in this specification, unless otherwise specified, the content unit "%" means "w/w%" and indicates the same numerical value as "g/100g".

<1. Oral composition>
The oral cavity composition according to the present embodiment contains a first component that is one or more selected from the group consisting of carbazocchrome, derivatives of carbazochrome, and salts thereof, and a second component that is a water-soluble polymer. The composition contains the first component in an amount of 0.04 w/w% or less.

[First component]
The oral composition according to the present embodiment contains a first component that is one or more selected from the group consisting of carbazochrome, carbazochrome derivatives, and salts thereof.

The first component has a hemostatic effect. The mechanism is thought to be that it exhibits a hemostatic effect by suppressing the increase in blood vessel permeability. Among the first components, the carbazochrome derivative should not be limited as long as it is pharmaceutically, pharmacologically (pharmacologically) or physiologically acceptable. Examples of carbazochrome derivatives include esterified derivatives, etherified derivatives, amidated derivatives, sulfonated derivatives, nitrated derivatives, nitrosated derivatives, and halogenated derivatives.

Salts of carbazochrome and carbazochrome derivatives should not be limited as long as they are pharmaceutically, pharmacologically (pharmacologically) or physiologically acceptable. Examples of salts of carbazochrome and carbazochrome derivatives include alkali metal salts and alkaline earth metal salts. Examples of alkali metal salts include sodium salts and potassium salts. Examples of alkaline earth metal salts include magnesium salts and calcium salts.

The first component is preferably sodium carbazochrome sulfonate or carbazochrome, and more preferably carbazochrome, from among one or more selected from the group consisting of carbazochrome, derivatives of carbazochrome, and salts thereof. Furthermore, as the first component, one or more selected from the group consisting of carbazochrome, derivatives of carbazochrome, and salts thereof, commercially available products can be used. As long as the first component is one or more selected from the group consisting of carbazochrome, carbazochrome derivatives, and salts thereof, they may be used alone or in combination of two or more. .

The oral composition contains 0.04 w/w% or less of the first component. That is, the content of the first component in the oral composition is 0.04 w/w% or less based on the total amount of the oral composition. The lower limit of the content of the first component should not be limited as long as it is 0.04 w/w% or less. Therefore, the content of the first component may be more than 0 w/w% and 0.04 w/w% or less, and within this range, the type of the first component, the type and content of other components, and the composition for oral cavity. It can be selected as appropriate depending on the intended use and its formulation form. When the content of the first component exceeds 0.04 w/w% based on the total amount of the oral composition, the remarkable effects of the present invention tend to be difficult to manifest.

The upper limit of the content of the first component is preferably, for example, 0.03 w/w% or less, and more preferably 0.02 w/w% or less, from the viewpoint of achieving more remarkable effects of the present invention. . Although the lower limit of the content of the first component should not be limited as described above, from the viewpoint of achieving more remarkable effects of the present invention and from the viewpoint of usability, it is preferable that the content is, for example, 0.001 w/w% or more. It is preferably 0.005 w/w% or more, more preferably 0.01 w/w% or more. The content of the first component is most preferably 0.02 w/w%.

[Second component]
The oral composition according to this embodiment contains a second component that is a water-soluble polymer. This second component is contained for the purpose of improving the adhesion and affinity of the oral composition to the oral mucosa. Among the second components, the salt of the water-soluble polymer should not be limited as long as it is pharmaceutically, pharmacologically (pharmacologically) or physiologically acceptable. As long as the second component is a water-soluble polymer defined by the definitions described below, these may be used alone or in combination of two or more, but the second component is It is preferable that two or more types of compounds are included.

Water-soluble polymers include, in terms of chemical composition, vinyl polymers such as polyvinyl alcohol (fully or partially saponified), polyvinylpyrrolidone (K25, K30, K90, etc.), carboxyvinyl polymers, polyacrylic acid, and their salts (sodium polyacrylate, etc.)], polysaccharides [cellulose polymers [e.g. methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose (hypromellose) (2208, 2906, 2910, etc.)], carboxymethyl cellulose, carboxy ethylcellulose, nitrocellulose and their salts (sodium carboxymethyl cellulose, etc.)], mucopolysaccharides [chondroitin sulfate, alginic acid, hyaluronic acid and their salts (sodium chondroitin sulfate, sodium alginate, sodium hyaluronate, etc.)], dextran (dextran 40 and dextran 70), pullulan, xanthan gum, gellan gum, agar, etc.]. Commercially available water-soluble polymers can be used.

The water-soluble polymer preferably has a number average molecular weight of 5,000 or more, more preferably 6,000 or more, even more preferably 7,000 or more, even more preferably 8,000 or more, and even more preferably 9,000 or more. is particularly preferable, and most preferably 10,000 or more. The number average molecular weight of the water-soluble polymer may be 5,000,000 or less, preferably 2,000,000 or less, and more preferably 1,000,000 or less.

The water-soluble polymer that is the second component is preferably an ionic water-soluble polymer from the viewpoint of more significantly achieving the effects of the present invention. Examples of ionic water-soluble polymers include carboxyvinyl polymers, polyacrylic acids, carboxymethylcellulose, carboxyethylcellulose, mucopolysaccharides, and salts thereof, and carboxyvinyl polymers, polyacrylic acids, carboxymethylcellulose, and mucopolysaccharides are preferred. and salts thereof, more preferably carboxyvinyl polymers, sodium carboxymethylcellulose, alginic acid, sodium alginate, still more preferably carboxyvinyl polymers and sodium carboxymethylcellulose, most preferably carboxyvinyl polymers. .

From another point of view, the second component is preferably a vinyl polymer or a polysaccharide, more preferably a vinyl polymer, and even more preferably a carboxyvinyl polymer, polyacrylic acid, or a salt thereof. Among them, carboxyvinyl polymers are particularly preferred.

From another viewpoint, the second component is preferably a cellulose polymer, a vinyl polymer, a mucopolysaccharide, or a pullulan, and one or two selected from the group consisting of hydroxypropylmethylcellulose, carboxyvinyl polymer, sodium alginate, and pullulan. It is more preferable to include more than one species.

The content of the second component in the oral composition should not be limited. Therefore, the content of the second component can be appropriately selected depending on its type, the type and content of other components, the use of the oral composition, its formulation form, etc. From the viewpoint of more significantly achieving the effects of the present invention, the oral cavity composition preferably contains the second component in an amount of 0.001 w/w% or more and 20 w/w% or less. That is, the content of the second component in the oral composition is preferably 0.001 to 20 w/w% based on the total amount of the oral composition. The content of the second component is more preferably 0.01 to 10 w/w%, most preferably 0.1 to 10 w/w%. Among these, it is particularly preferable that the content is 5 w/w% or less.

The content ratio of the first component and the second component in the oral composition should not be limited. Therefore, the content ratio of the first component and the second component is selected as appropriate depending on the types of the first component and the second component, the types and contents of other components, the use of the oral composition and its formulation form, etc. can do. From the viewpoint of achieving more remarkable effects of the present invention, the content ratio of the first component and the second component is, for example, 0.1 to 0.1 to 1 part by mass of the first component contained in the oral composition. Preferably, it is 5000 parts by mass. More preferably, the amount of the second component is 1 to 1000 parts by weight per 1 part by weight of the first component, and still more preferably 5 to 500 parts by weight per 1 part by weight of the first component. Among these, it is also preferable that the second component be 50 parts by mass or more, 70 parts by mass or more, or 90 parts by mass or more with respect to 1 part by mass of the first component.

[Third component]
It is preferable that the oral composition according to the present embodiment further contains a third component, which is an oily base, in addition to the first component and the second component. The oral cavity composition of the present embodiment further contains the third component in addition to the first component and the second component, so that the effects of the present invention are more prominently exhibited.

The third component, the oily base, should not be limited as long as it is pharmaceutically, pharmacologically (pharmacologically) or physiologically acceptable. As long as the third component is a specific compound described later as an oily base, it may be used alone or in combination of two or more.

As such an oily base, for example, one or two types selected from the group consisting of paraffins such as petrolatum, solid paraffin, liquid paraffin, and light liquid paraffin, white petrolatum, microcrystalline wax, white beeswax, and gelled hydrocarbons. The above can be mentioned. Among the above, white petrolatum, liquid paraffin, light liquid paraffin, microcrystalline wax, white beeswax, and gelled hydrocarbons can be preferably used. Among these, paraffins are preferred, and liquid paraffin and light liquid paraffin are more preferred. A commercially available oil base can also be used.

The content of the third component in the oral composition should not be limited. The content of the third component can be appropriately selected depending on its type, the type and content of other components, the use of the oral composition, its formulation form, etc. From the viewpoint of achieving more remarkable effects of the present invention, the content of the third component in the oral composition is preferably 1 to 95 w/w%, for example, 3 to 95 w/w%, based on the total amount of the oral composition. It is more preferably 90 w/w%, even more preferably 10 to 90 w/w%, even more preferably 30 to 90 w/w%, and particularly preferably 40 to 90 w/w%. , most preferably 50 to 85 w/w%.

The content ratio of the first component and the third component in the oral composition should not be limited. The content ratio of the first component and the third component is selected appropriately depending on the types of the first component and the third component, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of achieving more remarkable effects of the present invention, the content ratio of the first component and the third component is, for example, 5 to 100,000 parts by mass of the third component to 1 part by mass of the first component contained in the oral composition. Preferably. More preferably, the amount of the third component is 10 to 100,000 parts by mass per 1 part by mass of the first component, still more preferably 100 to 50,000 parts by mass per 1 part by mass of the first component, and More preferably, the amount of the third component is from 500 to 10,000 parts by weight per 1 part by weight of the first component, and most preferably from 1,000 to 5,000 parts by weight per 1 part by weight of the first component.

The content ratio of the second component and the third component in the oral composition should not be limited. The content ratio of the second component and the third component is appropriately selected depending on the types of the second and third components, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of achieving more remarkable effects of the present invention, the content ratio of the second component and the third component is, for example, 0.01 to 1 part by mass of the third component to 1 part by mass of the second component contained in the oral composition. Preferably, it is 1000 parts by mass. More preferably, the third component is 0.05 to 100 parts by mass per 1 part by mass of the second component, and even more preferably 0.1 to 50 parts by mass per 1 part by mass of the second component. Most preferably, the amount of the third component is 1 to 20 parts by mass per 1 part by mass of the second component.

[Fourth component]
The oral composition according to this embodiment preferably contains a fourth component that is a non-steroidal anti-inflammatory agent. When the oral cavity composition further contains the fourth component in addition to the first component and the second component, the effects of the present invention are more prominently exhibited. By further containing a third component therein, the effects of the present invention can be exhibited even more significantly. In addition, since the oral composition according to the present embodiment has improved adhesion to the oral mucosa, the anti-inflammatory effect of the fourth component and the Tissue repair effects can be exerted more efficiently.

The fourth component, the non-steroidal anti-inflammatory agent, should not be limited as long as it is pharmaceutically, pharmacologically (pharmacologically) or physiologically acceptable. As long as the fourth component is a specific compound described below as an anti-inflammatory agent, one type of these may be used alone, or two or more types may be used in combination.

Such non-steroidal anti-inflammatory agents include, for example, allantoin, ardioxa, ictamol, glycyrrhizic acid, glycyrrhetinic acid, salicylic acid, dimethylisopropyl azulene, indomethacin, epsilon-aminocaproic acid, berberine, pranoprofen, azulene sulfonic acid, diclofenac, bromfenac. , tranexamic acid, lysozyme chloride, bromelain, serrapeptase, ibuprofen piconol, presterone, derivatives thereof (allantoin chlorhydroxyaluminum, allantoin dihydroxyaluminum, methyl salicylate, salicylic acid monoglycol ester, etc.), and salts thereof One or more types of compounds are mentioned. Further, as a non-steroidal anti-inflammatory agent, tinctures having anti-inflammatory efficacy (chamomile tincture, myrrh tincture, latania tincture, rhubarb extract, etc.) can also be used. Commercially available anti-inflammatory agents can also be used.

Among the above, preferably one or more compounds selected from the group consisting of allantoin, glycyrrhizic acid, glycyrrhetinic acid, salicylic acid, epsilon-aminocaproic acid, azulene sulfonic acid, chamomile tincture, derivatives thereof, and salts thereof. be. Furthermore, one or more compounds selected from the group consisting of allantoin, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, β-glycyrrhetinic acid, allantoin chlorhydroxyaluminum, allantoin dihydroxyaluminum, epsilon-aminocaproic acid, and chamomile tincture. More preferably, it is allantoin and/or dipotassium glycyrrhizinate, even more preferably allantoin and/or dipotassium glycyrrhizinate, and most preferably allantoin.

The content of the fourth component in the oral composition should not be limited. The content of the fourth component can be appropriately selected depending on its type, the type and content of other components, the use of the oral composition, its formulation form, etc. From the viewpoint of achieving more remarkable effects of the present invention, the content of the fourth component in the oral composition is preferably, for example, 0.001 to 10 w/w%, based on the total amount of the oral composition, It is more preferably 0.01 to 5 w/w%, and most preferably 0.1 to 1 w/w%.

The content ratio of the first component and the fourth component in the oral composition should not be limited. The content ratio of the first component and the fourth component is selected as appropriate depending on the types of the first component and the fourth component, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of achieving more remarkable effects of the present invention, the content ratio of the first component and the fourth component is, for example, 0.01 to 0.01 to 1 part by mass of the first component contained in the oral composition. Preferably, it is 1000 parts by mass. More preferably, the amount of the fourth component is 0.1 to 500 parts by weight per 1 part by weight of the first component, and still more preferably 1 to 100 parts by weight per 1 part by weight of the first component. Most preferably, the amount of the fourth component is 10 to 50 parts by weight per 1 part by weight of the first component.

The content ratio of the second component and the fourth component in the oral composition should not be limited. The content ratio of the second component and the fourth component is appropriately selected depending on the types of the second component and the fourth component, the types and contents of other components, the use of the oral composition and its formulation form, etc. be able to. From the viewpoint of achieving more remarkable effects of the present invention, the content ratio of the second component and the fourth component is, for example, 0.00005 to 0.00005 to 1 part by mass of the second component contained in the oral composition. Preferably, it is 1000 parts by mass. More preferably, the fourth component is 0.0001 to 100 parts by mass per 1 part by mass of the second component, and even more preferably 0.0005 to 10 parts by mass per 1 part by mass of the second component. Even more preferably, the amount of the fourth component is from 0.001 to 4 parts by weight per 1 part by weight of the second component, and most preferably from 0.01 to 4 parts by weight per 1 part by weight of the second component. It is 1 part by mass.

[Other active ingredients (drug ingredients)]
The oral composition according to this embodiment may contain other active ingredients (drug ingredients) in addition to the above-mentioned components. Since the oral composition according to the present embodiment has improved adhesion to the oral mucosa, the effects of these drug components can be more efficiently exerted both at the initial stage when the oral composition is applied to the affected area and when it remains in the affected area over time. can be demonstrated. Examples of the above-mentioned active ingredients (drug ingredients) include bactericidal agents, antihistamines, tissue repair agents, local anesthetics, herbal medicines, vitamin preparations, steroidal anti-inflammatory agents, and other ingredients. The above-mentioned active ingredients (medicinal ingredients) may be used alone or in combination of two or more selected from the group consisting of these.

As disinfectants, for example, iodine, potassium iodide, liquid phenol, phenol, cetylpyridinium chloride, dequalinium chloride, creosote, thymol, triclocarban, benzalkonium chloride, benzethonium chloride, acrinol, oxidole, ethanol, isopropanol, mercurochrome, cresol. , isopropylmethylphenol, phenyl salicylate, sulfadiazine, homosulfamine, cinnamon oil, hinokitiol, and the like. In addition, it is preferable that the oral cavity composition according to this embodiment does not contain chlorhexidine gluconate. This is to eliminate the possibility of anaphylactic shock occurring if this is contained.

As antihistamines, for example, chlorpheniramine maleate, diphenhydramine salicylate, diphenylpyraline hydrochloride, mequitazine, triprolidine hydrochloride, carbinoxamine maleate, diphenhydramine hydrochloride, diphenhydramine tannate, dimenhydrinate, promethacin hydrochloride, promethazine theoculate, meclizine hydrochloride, isopentyl hydrochloride. Examples include.

Examples of tissue repair agents include sodium copper chlorophyllin, methylmethionine sulfonium chloride, sucralfate, cetraxate hydrochloride, sofalcon, gefarnate, trimebutine maleate, teprenone, and heparin-like substances.

Examples of local anesthetics include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, ethyl aminobenzoate, oxesazein, and thecaine.

Examples of herbal medicines include cinnamon bark, cinnamon bark oil, saiko, bukryō, trumpet root, clove ingredients, corydalis, ginger, bellflower, safflower, and the like.

Examples of vitamin preparations include vitamin A oil, retinol palmitate, retinol acetate, ascorbic acid, sodium ascorbate, calcium ascorbate, tocopherol, tocopherol acetate, tocopherol succinate, calcium tocopherol succinate, panthenol, sodium pantothenate, pantothenic acid. Calcium, pyridoxine hydrochloride, pyridoxal phosphate, vitamin B2, riboflavin, sodium riboflavin phosphate, riboflavin butyrate, sodium flavin adenine dinucleotide, hydroxocobalamin hydrochloride, hydroxocobalamin acetate, cyanocobalamin, hydroxocobalamin, nicotinamide, biotin, thiamine hydrochloride, Thiamine nitrate, bisthiamine nitrate, thiamine disulfide, thiamine dicetyl sulfate, dicethiamine hydrochloride, fursulthiamine hydrochloride, octothiamine, cicothiamine, bisbuthiamine, bisbenfotiamine, fursulthiamine, prosulthiamine, benfotiamine, etc. Can be mentioned.

Examples of steroidal anti-inflammatory agents include prednisolone, beclomethasone, triamcinolone, betamethasone, fluticasone, dexamethasone, hydrocortisone, and esters thereof (more specifically, esters of these with propionic acid, acetic acid, butyric acid, or valeric acid, etc.) For example, triamcinolone acetonide).

Other ingredients include local protective agents such as glycerin and concentrated glycerin, local irritants such as l-menthol, peppermint oil, and dl-menthol, tissue astringents such as hinokitiol, and blood circulation enhancers such as benzyl nicotinate and sodium polyethylene sulfonate. , antibiotics such as minocycline hydrochloride, etc.

〔Additive〕
The oral composition according to the present embodiment can contain various additives according to conventional methods depending on its use and formulation form, within a range that does not impair the effects of the present invention. Examples of such additives include various additives listed in "Dictionary of Pharmaceutical Additives 2007 (edited by Japan Pharmaceutical Excipients Association)".

Typical examples of additives include light silicic anhydride, silicic anhydride, pH adjusters, antioxidants, chelating agents, oils, colorants, fragrances, humectants, surfactants, and solvents.

Examples of pH adjusting agents include citric acid, adipic acid, tartaric acid, maleic acid, isocitric acid, fumaric acid, malic acid, succinic acid, gluconic acid, lactic acid, malonic acid, glutaric acid, glutaconic acid, aspartic acid, glutamic acid, and pimelic acid. , oxalic acid, glycolic acid, glyceric acid, pyruvic acid, acrylic acid, methacrylic acid, suberic acid, azelaic acid, mevalonic acid, ethylenediaminetetraacetic acid, phthalic acid, terephthalic acid, oxyacetic acid, phenylsuccinic acid, ethylmalonic acid, pivalin Acid, undecanoic acid, lauric acid, myristic acid, balmitic acid, stearic acid, behenic acid, N-palmitoyl-L-glutamic acid, ascorbic acid, pyrrolidone carboxylic acid, sulfamic acid, glucono delta-lactone, phosphoric acid, monopotassium phosphate , monosodium phosphate, calcium hydrogen phosphate, carbonic acid, boric acid, and other acidic substances.

Examples of antioxidants include tocopherols [tocopherol, tocopherol derivatives (tocopherol esters such as tocopherol acetate and tocopherol succinate)], fat-soluble antioxidants such as dibutylhydroxytoluene and butylhydroxyanisole, vitamin C, hydroquinone, cysteine, and glutathione. Examples include water-soluble antioxidants such as

Examples of chelating agents include sodium edetate, citric acid, and sodium citrate.

Examples of oils include sesame oil, castor oil, soybean oil, olive oil, squalane, and refined lanolin.

Examples of the coloring agent include Red No. 3, Blue No. 1, Yellow No. 4, Green No. 3, and titanium dioxide.

Natural fragrances such as peppermint oil, spearmint oil, eucalyptus oil, wintergreen oil, clove oil, thyme oil, sage oil, cardamom oil, rosemary oil, marjoram oil, lemon oil, nutmeg oil, lavender oil, paracress oil, etc. Essential oil, l-menthol, l-carvone, cinnamic aldehyde, orange oil, anethole, 1,8-cineole, methyl salicylate, eugenol, thymol, linalool, limonene, menthone, menthyl acetate, citral, camphor, borneol, pinene, spilanthol Fragrance components contained in the above natural essential oils such as ethyl acetate, ethyl butyrate, isoamyl acetate, hexanal, hexenal, methyl anthranilate, ethyl methyl phenyl glycidate, benzaldehyde, vanillin, ethyl vanillin, furaneol, maltol, ethyl Examples include flavor ingredients such as maltol, gamma/delta decalactone, gamma/deltaune decalactone, N-ethyl-p-menthane-3-carboxamide, menthyl lactate, and ethylene glycol-l-menthyl carbonate.

Further, as fragrances, apple, banana, strawberry, blueberry, melon, peach, pineapple, grape, muscat, wine, cherry, etc., which are made by combining one or more ingredients selected from the group consisting of the above-mentioned fragrance ingredients and natural essential oils. , squash, coffee, brandy, yogurt, and other concoction flavors.

As humectants, for example, glycerin, propylene glycol, polyethylene glycol (Macrogol 200, Macrogol 400, Macrogol 600, Macrogol 1000, Macrogol 1500, Macrogol 1540, Macrogol 4000, Macrogol 6000, etc.), sorbitol, 1 , polyhydric alcohols such as 3-butylene glycol, and starch syrup.

Examples of the surfactant include nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants. Nonionic surfactants include POE hydrogenated castor oil, POE sorbitan fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, (poly)glycerin fatty acid ester, fatty acid sorbitan, (poly)propylene glycol fatty acid ester, POE glycerin fatty acid ester, POE alkyl Examples include ether, POE-POP alkyl ether, and POE fatty acid ester. Examples of anionic surfactants include alkyl sulfates such as sodium lauryl sulfate. Examples of cationic surfactants include alkylammonium type surfactants. Examples of amphoteric surfactants include betaine type and imidazoline type.

Examples of the solvent include water, ethanol, glycerin, 1,3-butylene glycol, and the like.

[Dosage form]
The oral composition according to the present embodiment is in the form of liquid, paste, gel, etc., and can be used in dentifrices such as toothpaste, moist toothpaste, liquid toothpaste, mouthwash, gel, ointment, and mouth freshener. It can be prepared into various dosage forms such as gargling tablets, oral pasta, and gum. Furthermore, depending on the dosage form, known components other than the first component and second component can be blended within a range that does not impair the effects of the present invention, and the preparation can be carried out according to a conventional method.

The oral cavity composition according to this embodiment is preferably an oral ointment from the viewpoint of more significantly exhibiting the effects of the present invention. In the case of an oral ointment, for example, in the case of adults (15 years of age or older) and children of 7 years of age or older, it may be applied to the gums twice a day. The usage and dosage should not be limited to these, as long as they are effective and have few side effects.

It is also preferable that the oral composition according to this embodiment is an oral cream from the viewpoint of more significantly exhibiting the effects of the present invention. In the case of an oral cream, for example, for adults (15 years of age or older) and children of 7 years of age or older, the method of use includes applying it to a toothbrush twice a day and massaging the gums. The usage and dosage should not be limited to these as long as they achieve the effects of the present invention and have few side effects.

An example of the oral composition according to the present embodiment is provided in a laminate container in which part or all of the part that comes into contact with the oral composition is made of aluminum. Furthermore, examples include forms in which it is housed in a container made of glass or plastic.

[Hardness of oral composition]
The hardness of the oral composition according to this embodiment should not be limited as long as it is within a pharmaceutically, pharmacologically (pharmacologically) or physiologically acceptable range. However, from the viewpoint of achieving more remarkable effects of the present invention, the lower limit of the hardness of the oral composition is preferably 15 g or more, more preferably 20 g or more, and even more preferably 30 g or more. , more preferably 40 g or more, and most preferably 50 g or more. The upper limit of hardness is preferably 1000 g or less, more preferably 500 g or less, and even more preferably 300 g or less.

The hardness of the oral composition can be measured by the following method. That is, using a rheometer (product name (product number): FUDOH RHEO METER (RT2100D/D-CW), manufactured by Rheotec Co., Ltd.), T. The oral composition was prepared by filling a plastic ointment pot (No. A-55 (55cc), manufactured by MI Chemical Co., Ltd.) with a special adapter of φ20 (compressive elasticity) under the conditions of Speed (UP) 2cm/min and 25°C. The hardness of the oral cavity composition can be measured by taking the highest value of hardness (g) recorded until the depth reaches 1 cm.

[Adhesiveness of oral composition]
The oral composition according to the present embodiment includes a first component and a second component, and by containing the first component at 0.04 w/w% or less, the adhesiveness to the oral mucosa is significantly improved. can get. This effect is based on the fact that the oral cavity composition according to the present embodiment has a property of being swollen with moisture such as saliva in the oral cavity, thereby making it easier to adhere to affected areas such as the gums than before swelling. Therefore, whether or not the adhesion of the oral composition according to this embodiment to the oral mucosa is improved can be evaluated by the following method.

That is, when a predetermined probe is inserted into the oral composition after swelling and pulled up, the amount that adheres to the probe (hereinafter also referred to as "probe adhesion amount after swelling") is measured by the method described below. do. Furthermore, the amount of probe attached after swelling is measured using the same method for a composition that does not include both the first component and the second component (hereinafter also referred to as "comparative composition"). The amount of probe attached after swelling of the comparative composition obtained by this and the amount of probe attached after swelling of the oral cavity composition of this embodiment were compared, and when the amount of attached probe was increased, the oral cavity of this embodiment It can be determined that the composition has improved adhesion to the oral mucosa.

The method for measuring the amount of probe attached after the swelling of each composition is as follows. First, an oral composition is prepared by a conventional method. Comparative compositions are also prepared by conventional methods. Next, 2 mL each of purified water was added to 2 g of these oral compositions and 2 g of the comparative composition, mixed with stirring, and then left at 30° C. for 24 hours to swell, thereby swelling the oral compositions. Obtain swollen bodies of bodies and comparative compositions. Thereafter, 1.5 g of these swollen bodies were filled into 20 mL screw cap bottles (manufactured by Nichiden Rika Glass Co., Ltd.).

Then, using the above FUDOH RHEO METER, insert a dedicated probe with a diameter of 1 cm toward the surface of the swelling body filled in a screw cap bottle until its tip adheres to the surface of the swelling body, and then insert the probe at a speed of 2 cm/min. By pulling up the probe, the swelling body is attached to the probe, and the amount (mass) of the probe attached to the swelling body is measured. At this time, the larger the amount of the swollen substance attached to the probe, the better the adhesion to the oral mucosa. This is because the larger the amount of the swollen substance attached to the probe, the more likely it is to adhere to the affected area such as the gums.

Finally, by substituting the probe adhesion amount after swelling of the comparison composition and the probe adhesion amount after swelling of the oral composition into the following formula (1), the "adhesion amount change rate (%)" is calculated as follows: It is evaluated whether the adhesion of the oral composition to the oral mucosa is improved. "Adhesion amount change rate (%)" is
A positive number and a larger value mean that more of the swollen product of the oral composition adhered to the probe compared to the swelled product of the comparative composition. Therefore, when the "rate of change in adhesion amount (%)" is a positive number and is large, it can be evaluated that the oral composition has improved adhesion to the oral mucosa.

Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition (g) - Amount of probe adhesion after swelling of the comparative composition (g))/Amount of probe adhesion after swelling of the comparative composition (g)}×100...(1).

[Effect]
As described above, in this embodiment, it is possible to provide an oral composition with improved adhesion to oral mucosa.

[Target disease (use)]
The target diseases (uses) of the oral composition according to the present invention are not particularly limited as long as they are for the oral cavity, but include, for example, alleviating swelling of the gums, bleeding, pain, pus, alveolar pyorrhea, and stomatitis. , useful for amelioration, suppression or treatment. Furthermore, it is expected to have a tissue repair effect on the gums and a regeneration effect on the gums and periodontal ligament.

<2. Method for enhancing adhesion of oral composition to oral mucosa>
The method for enhancing the adhesion of an oral composition to oral mucosa according to the present embodiment is to make the oral composition adhere to the oral cavity. Specifically, a first step of preparing a first component that is one or more components selected from the group consisting of carbazocchrome, derivatives of carbazocrom, and salts thereof, and a second component that is a water-soluble polymer; and a second step of preparing an oral composition containing the component and the second component. In the second step, the first component is preferably blended in an amount of 0.04 w/w% or less with respect to the total amount of the oral composition. By incorporating 0.04 w/w% or less of the first component and the second component, the oral composition can significantly improve its adhesion to the oral mucosa.

[First step]
In the first step, a first component, which is one or more members selected from the group consisting of carbazocchrome, derivatives of carbazocrom, and salts thereof, and a second component, which is a water-soluble polymer, are prepared. The types of the first component and second component used in the first step are <1. Oral Composition>. Furthermore, in the first step, <1. Oral Composition> The third component, fourth component, other active ingredients, and additives described above may be prepared as necessary to prepare the oral composition in the second step described below.

[Second step]
In the second step, an oral composition containing the first component and the second component is prepared. Here, the first component and second component prepared in the first step, the third component, fourth component, other active ingredients, and additives prepared as necessary can be prepared according to conventional methods. At this time, the first component is blended in an amount of 0.04 w/w% or less with respect to the total amount of the oral composition. Regarding the amount of the second component to be blended in the second step, the types and amounts of other components, etc., <1. Oral Composition>. Regarding the formulation form and use of the oral composition produced according to the present embodiment, <1. Oral Composition>.

EXAMPLES Hereinafter, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited thereto.

[Manufacture of oral composition]
The oral composition of Example 1 was manufactured by preparing each component shown in Table 1 and preparing an oral composition containing each component according to a conventional method. Furthermore, each component shown in Table 1 was prepared, and comparative compositions of Comparative Examples 1 and 2 were manufactured in the same manner as in Example 1. "Carboxyvinyl polymer" in Table 1 is a water-soluble polymer, and was blended as the second component in this example. "Macrogol 400" and "Macrogol 4000" in Table 1 are each polyethylene glycol, and were blended into the oral compositions of Examples and Comparative Examples as humectants (additives).

[Test Example 1]
[Measurement and evaluation of probe adhesion amount after swelling of oral composition]
By adding 2 mL of purified water to 2 g of the oral composition of Example 1 and 2 g of the comparative compositions of Comparative Example 1 and Comparative Example 2, stirring and mixing, and leaving the mixture at 30° C. for 24 hours to swell. A swollen product of the oral composition of Example 1 and a swollen product of the comparative compositions of Comparative Example 1 and Comparative Example 2 were obtained. Thereafter, 1.5 g of these swollen bodies were filled into the above-mentioned screw cap bottles (manufactured by Nichiden Rika Glass Co., Ltd.) each having a capacity of 20 mL.

Then, using the above-mentioned FUDOH RHEO METER, insert a dedicated probe with a diameter of 1 cm toward the surface of the swelling body filled in a screw cap bottle until its tip adheres to the surface of the swelling body, and then insert the probe at a speed of 2 cm/min. The swelling body was attached to the probe by pulling up the probe, and the amount (mass) of the probe attached to the swelling body was measured.

Based on the above measurement, by substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 1 and the probe adhesion amount after swelling of the comparative composition of Comparative Example 2 into the following equation (2), "adhesion It was evaluated whether the comparative composition of Comparative Example 2 had improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 1 as "rate of change in amount (%)". Furthermore, by substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 1 and the probe adhesion amount after swelling of the oral composition of Example 1 into the following equation (3), "Adhesion amount change It was evaluated whether the oral composition of Example 1 had improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 1. As described above, when the value of "rate of change in adhesion amount (%)" is a positive number and is large, it can be evaluated that the oral composition has improved adhesion to the oral mucosa. The results are shown in Table 1.

Equations (2) and (3) are as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the comparative composition of Comparative Example 2 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 1 (g))/Comparative Example 1 Probe adhesion amount after swelling of comparative composition (g)}×100...(2)
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 1 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 1 (g)) / Comparative Example Amount of probe attached after swelling of comparative composition No. 1 (g)}×100 (3).

From Table 1, it can be seen that the oral composition of Example 1 exhibited a rate of change in the amount of adhesion that increased by 8.5% compared to the comparative composition of Comparative Example 1. It is understood that it is improving. Furthermore, the comparative composition of Comparative Example 2 is understood to have improved adhesion to the oral mucosa than the comparative composition of Comparative Example 1 because it contains carbazochrome; was not less than 0.04 w/w%, so the adhesion to the oral mucosa was not significantly improved compared to the oral composition of Example 1. That is, the oral composition of Example 1 contains a first component and a second component whose content is 0.02 w/w% (0.04 w/w% or less), so In comparison, the adhesion to the oral mucosa is significantly improved.

[Test Example 2]
[Measurement and evaluation of swelling properties of oral compositions]
0.5 g of the oral composition of Example 1 and 0.5 g of the comparative compositions of Comparative Examples 1 and 2 were each injected into a plastic syringe with a capacity of 2.5 mL (trade name: "Terumo Syringe", Terumo Corporation). (manufactured by the company) with the plunger removed. After measuring the total mass of the filled composition and the plastic syringe, 300 μL of purified water was added to each syringe. Furthermore, the cap portion (cut from the tube) of a 2 mL capacity tube (“trade name”: BIO-BIK Microtube, manufactured by Ina Optica Co., Ltd.) was attached to the plunger insertion opening portion of the syringe. Next, the syringe is held so that the longitudinal direction thereof is vertical and the portion where the cap is attached is located above the syringe, and the oral composition is allowed to swell by standing at room temperature for 24 hours. I let it happen. Thereafter, the syringe was turned upside down so that the part to which the cap was attached was placed on the lower side, and the syringe was left standing at an angle of 50° for 3 minutes to prevent swelling. The purified water was introduced into the cap section. Finally, the cap portion was removed, and the mass of the composition remaining in the syringe was measured.

By substituting the mass of the above composition before and after swelling into the following formula (4), the swelling rate (%) of the oral composition of Example 1 and the comparative compositions of Comparative Examples 1 and 2 was calculated. . It can be evaluated that the larger the value of this "swelling ratio (%)" is, the easier it is to swell and the faster the adhesive property is exhibited. The difference in expansion rate (%) between Example 1 and Comparative Example 2 and Comparative Example 1 was calculated and is shown in Table 2.

Equation (4) is as follows.
Swelling rate (%) = mass after swelling (g)/mass before swelling (g) x 100 (4).

From Table 2, it can be seen that the oral composition of Example 1 had an improved swelling rate of 4.2% compared to the comparative composition of Comparative Example 1, so it was easy to swell when applied to the oral mucosa. It is understood that it is in a state where it is easy to adhere to mucous membranes. Furthermore, although it is understood that the comparative composition of Comparative Example 2 has improved swelling properties than the comparative composition of Comparative Example 1 because it contains carbazochrome, the composition for oral cavity of Example 1 There was only a slight improvement in swelling properties compared to the standard. That is, the oral composition of Example 1 contains a first component having a carbazocchrome content of 0.02 w/w% (0.04 w/w% or less) and a second component; The swelling property in the oral mucosa is significantly improved compared to .

Furthermore, the oral composition of Example 1 has improved swelling properties, so that it not only adheres quickly to the oral mucosa, but also allows the oral composition to fill more gaps when applied to the oral mucosa and swells. Since it comes into contact with the application part, it is possible to improve the adhesion between the oral composition and the application part. At the same time, the retention effect in the application area is enhanced; for example, by staying inside the periodontal pocket, the effect of each component on the periodontal ligament part existing inside the gums can be enhanced.

[Test Example 3]
[Manufacture of oral composition]
The oral compositions of Examples 2 to 4 were prepared by preparing each component shown in Table 3 and preparing an oral composition containing each component according to a conventional method. Furthermore, each component shown in Table 3 was prepared, and comparative compositions of Comparative Examples 3 to 5 were produced in the same manner as in Examples 2 to 4. "Hypromellose 2910", "sodium alginate" and "pullulan" in Table 3 are water-soluble polymers and are therefore the second component. "Allantoin" in Table 3 is a non-steroidal anti-inflammatory agent, so it is the fourth component. "Macrogol 400" and "Macrogol 4000" in Table 3 are each polyethylene glycol and are therefore wetting agents (additives).

[Measurement and evaluation of probe adhesion amount after swelling of oral composition]
To 2 g each of the oral compositions of Examples 2 to 4 and 2 g of the comparative compositions of Comparative Examples 3 to 5, 2 mL of purified water was added, stirred and mixed, and left at 30° C. for 24 hours. Swollen bodies of the oral cavity compositions of Examples 2 to 4 and swollen bodies of the comparative compositions of Comparative Examples 3 to 5 were obtained by swelling the compositions. Thereafter, 1.5 g of these swollen bodies were filled into the same 20 mL screw cap bottles used in Test Example 1, respectively.

Then, using the above-mentioned FUDOH RHEO METER, insert a dedicated probe with a diameter of 1 cm toward the surface of the swelling body filled in a screw cap bottle until its tip adheres to the surface of the swelling body, and then insert the probe at a speed of 2 cm/min. The swelling body was attached to the probe by pulling up the probe, and the amount (mass) of the probe attached to the swelling body was measured.

Based on the above measurement, by substituting the amount of probe attached after swelling of the comparative composition of Comparative Example 3 and the amount of probe attached after swelling of the oral composition of Example 2 into the following equation (5), " It was evaluated whether or not the oral composition of Example 2 had improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 3 as "rate of change in adhesion amount (%)".

Furthermore, by substituting the probe adhesion amount after swelling of the comparative composition of Comparative Example 4 and the probe adhesion amount after swelling of the oral composition of Example 3 into the following equation (6), the following equation (6) is calculated. (%)'', it was evaluated whether the oral composition of Example 3 had improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 4. By substituting the amount of probe attached after swelling of the comparative composition of Comparative Example 5 and the amount of probe attached after swelling of the oral composition of Example 4 into the following formula (7), "
It was also evaluated whether the oral composition of Example 4 had improved adhesion to the oral mucosa compared to the comparative composition of Comparative Example 5 as "rate of change in adhesion amount (%)".

As in Test Example 1, when the "rate of change in adhesion amount (%)" is a positive number and the value is large, the oral composition can be evaluated as having improved adhesion to the oral mucosa. . The results are shown in Table 3.

Equation (5) is as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 2 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 3 (g)) / Comparative Example Probe adhesion amount (g) of comparative composition No. 3 after swelling}×100 (5).

Equation (6) is as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 3 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 4 (g)) / Comparative Example Probe adhesion amount (g) of comparative composition No. 4 after swelling}×100 (6).

Equation (7) is as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 4 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 5 (g)) / Comparative Example Amount of probe attached after swelling of the comparative composition of No. 5 (g)}×100 (7).

From Table 3, the oral composition of Example 2 showed a rate of change in the amount of adhesion that increased by 9.7% compared to the comparative composition of Comparative Example 3. It is understood that the adhesion to is improved. Furthermore, the oral composition of Example 3 showed a rate of change in the amount of adhesion that increased by 13.5% compared to the comparative composition of Comparative Example 4, and the oral composition of Example 4 showed Since the rate of change in the amount of adhesion was increased by 13.0% compared to the comparative composition No. 5, Examples 3 and 4 also had a greater effect on the oral mucosa than Comparative Example 4 and Comparative Example 5, respectively. It is understood that the adhesion is further improved.

[Test Example 4]
[Manufacture of oral composition]
The oral compositions of Examples 5 to 8 were prepared by preparing each component shown in Table 4 and preparing an oral composition containing each component according to a conventional method. Furthermore, each component shown in Table 4 was prepared, and a comparative composition of Comparative Example 6 was produced in the same manner as in Examples 5 to 8. "Carboxyvinyl polymer,""sodiumalginate," and "pullulan" in Table 4 are each water-soluble polymers, so they are the second components. "Liquid paraffin" in Table 4 is an oily base, so it is the third component. "Allantoin" in Table 4 is a non-steroidal anti-inflammatory agent, so it is the fourth component. In each Example and Comparative Example in Test Example 4, the dosage form was an oral cream instead of the oral ointment in each Example and Comparative Example of Test Example 1 and Test Example 3.

[Measurement and evaluation of probe adhesion amount after swelling of oral composition]
To 2 g of each of the oral compositions of Examples 5 to 8 and 2 g of the comparative composition of Comparative Example 6, 2 mL of purified water was added, stirred and mixed, and left at 30° C. for 24 hours to swell. Thus, swollen bodies of the oral compositions of Examples 5 to 8 and swollen bodies of the comparative composition of Comparative Example 6 were obtained, respectively. Thereafter, 1.5 g of these swollen bodies were filled into the same 20 mL screw cap bottles used in Test Example 1, respectively.

Then, using the above-mentioned FUDOH RHEO METER, insert a dedicated probe with a diameter of 1 cm toward the surface of the swelling body filled in a screw cap bottle until its tip adheres to the surface of the swelling body, and then insert the probe at a speed of 2 cm/min. The swelling body was attached to the probe by pulling up the probe, and the amount (mass) of the probe attached to the swelling body was measured.

Based on the above measurement, the amount of probe adhesion after swelling of each of the oral compositions of Examples 5 to 8 is calculated using the following formula (8) with respect to the amount of probe adhesion after swelling of the comparative composition of Comparative Example 6. By substituting the applicable one of ~(11), the oral compositions of Examples 5 to 8 were compared to the comparative composition of Comparative Example 6 as "rate of change in adhesion amount (%)". We evaluated whether or not the adhesion to was improved. Similarly to Test Example 1, when the "rate of change in adhesion amount (%)" is a positive number and the value is large, the oral composition can be evaluated as having improved adhesion to the oral mucosa. can. The results are shown in Table 4.

Equation (8) is as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 5 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Probe adhesion amount (g) of comparative composition No. 6 after swelling}×100 (8).

Equation (9) is as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 6 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Probe adhesion amount (g) of comparative composition No. 6 after swelling}×100 (9).

Equation (10) is as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 7 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Probe adhesion amount (g) of comparative composition No. 6 after swelling}×100 (10).

Equation (11) is as follows.
Rate of change in adhesion amount (%) = {(Amount of probe adhesion after swelling of the oral composition of Example 8 (g) - Amount of probe adhesion after swelling of the comparative composition of Comparative Example 6 (g)) / Comparative Example Probe adhesion amount (g) after swelling of comparative composition No. 6}×100 (11).

From Table 4, the oral composition of Example 5 showed a rate of change in the amount of adhesion that increased by 77.7% compared to the comparative composition of Comparative Example 6. It is understood that the adhesion to is improved. Furthermore, as shown in Table 4, the rate of change in the amount of adhesion was A tendency to further increase was confirmed.

[Formulation example]
Hereinafter, some formulation examples using the oral composition according to the present invention will be explained. The following formulation examples can be prepared by conventional methods using the formulations described below. The unit of content of each component is w/w%.

[Formulation example 1] Macrogol ointment carbazocchrome 0.02
Carboxyvinyl polymer 3
Macro goal 400 48.49
Macrogol 4000 remaining amount 100.0 w/w%.

An example of a formulation related to Formulation Example 1 above is an example in which the macrogol ointment of Formulation Example 1 is filled into a metal container.

[Formulation Example 2] Ointment Carbazochrome 0.02
Allantoin 0.3
Carboxyvinyl polymer 2
Tocopherol acetate 2
white vaseline 30
Microcrystalline wax 2
White beeswax 2
Peppermint oil 0.1
Gelled hydrocarbon Total remaining amount 100.0 w/w%.

An example of a formulation related to Formulation Example 2 above is an example in which the ointment of Formulation Example 2 above is filled into an aluminum container.

[Formulation Example 3] Ointment Carbazochrome 0.02
Cetylpyridinium chloride hydrate 0.05
Hinokitiol 0.1
Sodium alginate 3
Gelled hydrocarbon Total remaining amount 100.0 w/w%.

An example of a formulation related to Formulation Example 3 above is an example in which the ointment of Formulation Example 3 above is filled into an aluminum container.

[Formulation Example 4] O/W Cream Carbazochrome 0.02
Dipotassium glycyrrhizinate 0.4
Silicic anhydride 1
Liquid paraffin 5
Hydroxypropyl methylcellulose 1
glycerin 5
Sorbitan monostearate 0.3
Polyoxyethylene hydrogenated castor oil 3
Purified water Total remaining amount 100.0 w/w%.

As a formulation example related to Formulation Example 4 above, there can be mentioned an example in which the O/W cream of Formulation Example 4 above is filled into a laminate container.

[Formulation Example 5] Mouthwash Carbazochrome 0.02
Ethanol 10
Propylene glycol 10
Sodium lauryl sulfate 0.5
xylitol 1
Paraben 0.2
Carmellose sodium 1
Purified water Total remaining amount 100.0 w/w%.

As a formulation example related to Formulation Example 5 above, there can be mentioned an example in which the mouthwash of Formulation Example 5 above is filled into a container made of polyethylene terephthalate.

Although the embodiments and examples of the present invention have been described above, it is planned from the beginning that the configurations of the above-mentioned embodiments and examples may be combined as appropriate or modified in various ways. .

The embodiments and examples disclosed herein are illustrative in all respects and should not be considered restrictive. The scope of the present invention is indicated by the claims rather than the embodiments described above, and it is intended that equivalent meanings to the claims and all changes within the scope are included.

Claims (5)

a first component that is one or more members selected from the group consisting of carbazochrome, derivatives of carbazochrome, and salts thereof;
a second component that is a water-soluble polymer;
a third component which is an oily base;
A method for producing an oral composition comprising:
preparing the first component, the second component, and the third component ;
preparing an oral composition comprising the first component, the second component , and the third component ,
The second component is one or more selected from the group consisting of vinyl polymers and polysaccharides,
The vinyl polymer is one or more selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, polyacrylic acid, and salts thereof,
The polysaccharides include methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxyethylcellulose, nitrocellulose, chondroitin sulfate, alginic acid, hyaluronic acid, dextran, pullulan, xanthan gum, gellan gum, agar and salts thereof. One or more types selected from the group consisting of,
The third component is white petrolatum,
The carbazochrome derivative is one or more selected from the group consisting of esterified derivatives, etherified derivatives, amidated derivatives, sulfonated derivatives, nitrated derivatives, nitrosated derivatives, and halogenated derivatives of carbazochrome,
The content ratio of the second component to 1 part by mass of the first component is 5 parts by mass or more and 500 parts by mass or less,
The content ratio of the third component to 1 part by mass of the first component is 5 parts by mass or more and 100,000 parts by mass or less,
The method for producing an oral composition, wherein the oral composition contains the first component in an amount of more than 0 w/w% and no more than 0.04 w/w% based on the total amount of the oral composition. a first component that is one or more members selected from the group consisting of carbazochrome, derivatives of carbazochrome, and salts thereof;
a second component that is a water-soluble polymer;
a third component which is an oily base;
including the step of incorporating into the oral composition,
The second component is one or more selected from the group consisting of vinyl polymers and polysaccharides,
The vinyl polymer is one or more selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, polyacrylic acid, and salts thereof,
The polysaccharides include methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxyethylcellulose, nitrocellulose, chondroitin sulfate, alginic acid, hyaluronic acid, dextran, pullulan, xanthan gum, gellan gum, agar and salts thereof. One or more types selected from the group consisting of,
The third component is white petrolatum,
The carbazochrome derivative is one or more selected from the group consisting of esterified derivatives, etherified derivatives, amidated derivatives, sulfonated derivatives, nitrated derivatives, nitrosated derivatives, and halogenated derivatives of carbazochrome,
The content ratio of the second component to 1 part by mass of the first component is 5 parts by mass or more and 500 parts by mass or less,
The content ratio of the third component to 1 part by mass of the first component is 5 parts by mass or more and 100,000 parts by mass or less,
The oral composition contains the first component in an amount of more than 0 w/w% and 0.04 w/w% or less based on the total amount of the oral composition, and has good adhesion to the oral application part of the oral composition. How to improve. The method for improving the adhesion of the oral composition to the oral cavity application portion according to claim 2, wherein the oral composition further contains allantoin. a first component that is one or more members selected from the group consisting of carbazochrome, derivatives of carbazochrome, and salts thereof;
a second component that is a water-soluble polymer;
a third component which is an oily base;
including the step of incorporating into the oral composition,
The second component is one or more selected from the group consisting of vinyl polymers and polysaccharides,
The vinyl polymer is one or more selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, polyacrylic acid, and salts thereof,
The polysaccharides include methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, carboxyethylcellulose, nitrocellulose, chondroitin sulfate, alginic acid, hyaluronic acid, dextran, pullulan, xanthan gum, gellan gum, agar and salts thereof. One or more types selected from the group consisting of,
The third component is white petrolatum,
The carbazochrome derivative is one or more selected from the group consisting of esterified derivatives, etherified derivatives, amidated derivatives, sulfonated derivatives, nitrated derivatives, nitrosated derivatives, and halogenated derivatives of carbazochrome,
The content ratio of the second component to 1 part by mass of the first component is 5 parts by mass or more and 500 parts by mass or less,
The content ratio of the third component to 1 part by mass of the first component is 5 parts by mass or more and 100,000 parts by mass or less,
The oral cavity composition contains the first component in an amount of more than 0 w/w% and 0.04 w/w% or less based on the total amount of the oral composition, and has a retention property in the oral cavity application part of the oral composition. How to improve. The method for improving the retention of an oral composition in an intraorally applied part according to claim 4, wherein the oral composition further contains allantoin.